ReviewBioengineering (Basel, Switzerland)2020
Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption.
Review in Bioengineering (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Automated culture and monitoring of a high-throughput human heart-on-a-chip.bioRxiv : the preprint server for biology · 2026Article
- Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation.Biosensors · 2026Review
- Bridging the Gap: How Organ-on-a-Chip Technology Facilitates the Battle against Glioma.Small science · 2026Review
- Potential of organ-on-a-chip in advancing synthetic extracellular matrix technology for bone tissue engineering in dentistry (Review).Biomedical reports · 2026Review
- Skin-on-chip: Quo vadis?APL bioengineering · 2025Review
- From Spheroids to Tumor-on-a-Chip for Cancer Modeling and Therapeutic Testing.Micromachines · 2025Review
- Organ-on-a-Chip Models of the Female Reproductive System: Current Progress and Future Perspectives.Micromachines · 2025Review
- Cancer-on-chip: a breakthrough organ-on-a-chip technology in cancer cell modeling.Medical & biological engineering & computing · 2025Review
- Efforts to evaluate translational science's impact on biomedicine and society should incorporate Science and Technology Studies (STS).Journal of clinical and translational science · 2025Article
- Development of a robotic-assisted handling and manipulation system for the high-scale bioproduction of 3D-bioprinted organ-on-a-chip devices.HardwareX · 2024Article
- Technology Readiness Level Roadmap for Developing Innovative Herbal Medicinal Products.Pharmaceuticals (Basel, Switzerland) · 2024Article
- An Insight on Microfluidic Organ-on-a-Chip Models for PMACS omega · 2024Review
- Big Question to Developing Solutions: A Decade of Progress in the Development of Aquatic New Approach Methodologies from 2012 to 2022.Environmental toxicology and chemistry · 2024Article
- In vitro high-content tissue models to address precision medicine challenges.Molecular aspects of medicine · 2023Review
- Design and evaluation of a skin-on-a-chip pumpless microfluidic device.Scientific reports · 2023Article
- Review
- Merging microfluidics with luminescence immunoassays for urgent point-of-care diagnostics of COVID-19.Trends in analytical chemistry : TRAC · 2022Review
- Organs-on-Chips Platforms Are Everywhere: A Zoom on Biomedical Investigation.Bioengineering (Basel, Switzerland) · 2022Review
- Boosting the Clinical Translation of Organ-on-a-Chip Technology.Bioengineering (Basel, Switzerland) · 2022Article
- Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium.Toxicological sciences : an official journal of the Society of Toxicology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Organs-on-a-Chip (OOAC) is a disruptive technology with widely recognized potential to change the efficiency, effectiveness, and costs of the drug discovery process; to advance insights into human biology; to enable clinical research where human trials are not feasible. However, further development is needed for the successful adoption and acceptance of this technology. Areas for improvement include technological maturity, more robust validation of translational and predictive in vivo-like biology, and requirements of tighter quality standards for commercial viability. In this review, we reported on the consensus around existing challenges and necessary performance benchmarks that are required toward the broader adoption of OOACs in the next five years, and we defined a potential roadmap for future translational development of OOAC technology. We provided a clear snapshot of the current developmental stage of OOAC commercialization, including existing platforms, ancillary technologies, and tools required for the use of OOAC devices, and analyze their technology readiness levels. Using data gathered from OOAC developers and end-users, we identified prevalent challenges faced by the community, strategic trends and requirements driving OOAC technology development, and existing technological bottlenecks that could be outsourced or leveraged by active collaborations with academia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.